Results 61 to 70 of about 6,459 (257)

A Rare Case of Tirzepatide-Induced Hepatitis: Causality Assessment With the RUCAM Criteria

Annals of Internal Medicine: Clinical Cases
Tirzepatide is an effective medication that targets both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, resulting in weight loss, improved glycemic control, and better cardiovascular and renal outcomes.
Rayan Tareg Ahmed, Cinderella Ali Almatrooshi, Sana Jasem AlShehhi, Mahamad Tarik Bakri   +3 more
doaj   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta‐analysis

Journal of Diabetes Investigation
Objective To investigate the risk of biliary diseases in patients with type 2 diabetes mellitus (T2DM) or obesity treated with tirzepatide. Methods Literature searches were performed using the PubMed, Web of Science, Cochrane Library, and CNKI databases ...
Jie Gong, Fengwei Gao, Kangyi Jiang, Qingyun Xie, Xin Zhao, Zehua Lei   +5 more
doaj   +1 more source

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials

Pharmaceuticals
Background: Obesity and type 2 diabetes (T2D) are major public health concerns. Tirzepatide has shown promise in recent clinical trials. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide in adults with ...
Ligang Liu, Hekai Shi, Merilyn Xie, Yuxiao Sun, Milap C. Nahata   +4 more
doaj   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025

Obesity, EarlyView.
ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard, Jacob Harbo Andersen, Rebecca Kofod Vinding, Julie Tonsgaard Kloppenborg, Anton Pottegård   +4 more
wiley   +1 more source

Case Report: Rhabdomyolysis following initiation of tirzepatide

Frontiers in Pharmacology
We present the case of a 66-year-old woman who developed weakness, nausea, and vomiting accompanied by markedly elevated creatine kinase levels after first treatment with an increased dose of tirzepatide.
Jonas Michael Bodanowitz, Isabell Mattes, Micha Loebermann, Carlos Fritzsche   +3 more
doaj   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Six‐ and Twelve‐Month Changes in Body Composition and 24‐h Energy Expenditure After a Very Low‐Calorie Ketogenic Diet

Obesity, EarlyView.
ABSTRACT Objective This study assessed changes in body composition and 24‐h energy metabolism at 6 and 12 months after initiation of a 1‐month very low‐calorie ketogenic diet (VLCKD) in women with obesity. Methods Seventeen women with obesity who completed a 1‐month VLCKD underwent a 4‐week transition phase with carbohydrate reintroduction, followed by
Alessio Basolo, Paolo Piaggi, Valentina Angeli, Paola Fierabracci, Chiara Bologna, Giordano Paolucci, Guido Salvetti, Luca Chiovato, Jonathan Krakoff, Alberto Landi, Ferruccio Santini   +10 more
wiley   +1 more source

Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol

Obesity Pillars
Introduction: Obesity and its downstream effects continue to drive rising rates of chronic disease. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant ...
Jessica Duncan, Patrick Lee Stevens, Emily Bigby, Courtney Floyd, Josh Malina, Jennifer Nickens, Amber Lambert, Taylor Kantor   +7 more
doaj   +1 more source

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. [PDF]

Endocrinol Diabetes Metab
Tirzepatide 15 mg and cagrilintide–semaglutide (CagriSema) achieve the greatest percent body weight reduction (−17.97% and −17.46%, respectively) and the highest rates of ≥ 20% weight loss versus placebo in this network meta‐analysis of 25 randomized trials.
Hamarsheh S, Jaber AR, Abu-Khazneh O, Andonie CR, Majadleh S, Zahran A, Ayesh H.   +6 more
europepmc   +2 more sources